Lupin Ltd - GSpiriva on a Healthy Growth Track, Headwinds Receding
This to result in $200-220 million sales on a quarterly basis. USFDA recently completed cGMP inspection of Dabhasa plant and zconcluded with no...
165 Views
LUPIN Ltd - Margins Guidance Increased
The company’s sales increased by 20.2% YoY to Rs 5,197 Cr, and the growth was majorly led by its US business of $212 (+0.5% Q0Q).
412 Views
LUPIN Ltd - Positive Outlook Backed by the Launch of Niche Products
The company’s sales were up 28.6% YoY at Rs 4,330 Cr, and the growth was majorily led by its India business (+9.8% YoY), EMEA (+19.6% YoY)
265 Views
Pick of the Week: Lupin Ltd - 10 JULY 2023
Lupin is an innovation-led transnational pharmaceutical company. It, develops and commercializes a wide range of branded and generic formulations,...
248 Views
Lupin - GSpiriva Approval a Overall Turnaround in The Business
Lupin has received approval from generic version of Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) from USFDA in the US Market.
271 Views